📈 Join us for LIVE TRADING action all day long in the 📈
Market Master’s trading room
Last night, I was kicking myself for not holding Gamestop (GME) overnight, as it rallied another 50% in after-hours trading.
Then, this morning, the company issued news that sent the stock lower and took back all of those gains in an hour!
This is by far the most volatile stock to trade right now, and I am feeling pretty good about locking up my $8000+ profit on it yesterday, and not risking it overnight.
👉“Roaring Kitty,” the social media star behind the surge in interest for GME, is doing a live broadcast at 12pm EST today. You can catch it live in the Market Master’s trading room.
Today, however, I have my eye on another stock that hasn’t been making headlines like GME, but it has been delivering the same type of gains to traders.
I’ve talked about this one several times over the last year. If you have been following it, you saw it gain over 300% at one point after I talked about it last time in March.
I am banging the table on it again right now! 💥
Go to your favorite platform and pull up MAIA Biotechnology (MAIA) right now and I’ll show you why I am so hot on this one today.
MAIA has been executing incredibly well over the last year, and the stock has been reflecting that.
In the chart below, I wanted to visually show you how that has looked since I brought it up last time…
Notice that all of the pullbacks have been brief, and then the stock went on to make new highs.
When I saw the stock selloff from nearly $6 to just $3 this week, I couldn’t believe it!
You know, I don’t like to try to pick up “falling knives” when it comes to buying stocks because you just never know how far they will decline before bouncing back.
What I like to look for is the stock back above the 20-hour level, for several hours.
Well, look at where MAIA is on the chart right now… it is sitting right there!
I love this area because it provides a great risk/reward level for me to consider.
If the stock drops back under the $3.10 lows from earlier in the week, I could use that as a good stop-loss level. It would be pretty manageable for me if that happened.
On the other hand, MAIA has already established an upside range all the way to nearly $6 – that could be a massive move from this level.
Small loss… or, potential for big gains. That is exactly the kind of setup I am looking for.
I don’t know what is going to happen with the stock, of course, and I never want to try to tell you what to do in your personal trading. I am simply showing you a great-looking setup in real-time that we can watch and then study the results.
Another factor that gives me confidence in this setup is that MAIA has already bounced 20% higher from Wednesday’s lows.
Even though it pulled back from there, it didn’t break the $3.10 level it established on Wednesday. That is a crucial sign for a base to form.
MAIA will be a very exciting stock to watch today, so make sure you have eyes on it all day long!
As some background on the company, MAIA Biotechnology, Inc. (MAIA) is a clinical-stage biopharmaceutical company exploring genuinely groundbreaking cancer treatments.
Its lead asset — called THIO — “is the only direct telomere targeting agent currently in clinical development.”
Its action in cancer treatment has been featured in renowned publications such as Cancer Cell and Nature.
Here’s how it works…
There’s an enzyme called telomerase that’s present in 85% to 90% of human cancers and that “contributes significantly to the proliferation and reproductive immortality of cancer cells.”
According to the company, “THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death.”
On top of killing the cancer cells directly, THIO — coupled with an immune checkpoint inhibitor — seems to produce an immune memory specific to cancer cells “where the immune system [continues] to be active against the cancer cells after extended periods of time, with no additional treatment.”
If you know anything about cancer, you know that maintaining remission is the truly critical part of therapy, and THIO is showing promise in that respect.
On February 22, MAIA announced the completed enrollment of its Phase 2 clinical trial for THIO in cases of non-small cell lung cancer (NSCLC), noting that “preliminary data has demonstrated unprecedented rates of disease control and response to date.”
And just on Tuesday, the company revealed new data on the trial, including a favorable overall response rate of 38% and a disease control rate of 85%.
MAIA CEO Vlad Vitoc said, “All exceptional measures of efficacy in our trial to date have exceeded our own expectations and outperformed standard of care treatments.”
He added that the data “advances THIO’s excellent clinical profile as a strong, safe, and highly effective alternative for patients who progressed following chemotherapy and other available treatments. We eagerly anticipate full efficacy data from THIO-101 in the second half of this year.”
MAIA notes that NSCLC is “the largest tumor type globally by mortality (1.7 million deaths annually) and dollar sales ($34 billion annually).”
However, it appears that THIO may have applications well beyond NSCLC…
For instance, it has been granted three Orphan Drug Designations (ODD) by the FDA for “hepatocellular carcinoma (the dominant histology of primary liver cancers, ~90%), small cell lung cancer (the deadliest type of lung cancer), and malignant gliomas (the deadliest group of brain cancers, including glioblastomas).”
These designations afford the company seven years of U.S. market exclusivity after drug approval and tax credits for qualified clinical testing.
In an upcoming second clinical trial, MAIA will be pitting THIO against the likes of small cell lung cancer, liver cancer, and colorectal cancer.
On top of all this, MAIA is developing a second generation of THIO-derived drugs. They’ve developed more than 80 to date, with three U.S. patent applications.
According to the company, “Preclinical studies of several of these agents have shown highly significant anti-cancer efficacy at low dose levels in multiple in vivo and in vitro models.”
For a more detailed breakdown of MAIA’s trial progress and drug pipeline, check out this press release that the company put out yesterday detailing year-to-date progress.
In March, the company did a $2.9 million private placement, and five of the company’s independent directors participated, with two of them each purchasing $200,000 worth of shares.
One of those directors purchased an additional $300,000 worth of shares the following month, even after the stock price had more than doubled.
As the CEO Vlad Vitoc noted, the directors’ investments “point to their confidence in the science and clinical pathways for our immuno-oncology therapies targeting difficult-to-treat cancers.”
Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.
Bottom line: This has been one of the top-performing stocks this year. There have not been many pullback opportunities, and they have all been aggressively bought up in the past. While we never know what the future holds, I think this is an excellent spot to take a look at MAIA again.
I am expecting a big move (one way or another!) for MAIA very soon.
Make sure that you are watching MAIA even before the market opens today!
To Your Success,
Jeff Bishop
P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now.
*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”
Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we currently have received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 13, 2024. Previously, we received twelve thousand five hundred dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 7, 2024. Also, we were paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc for a one day marketing program on March 6, 2024. We were also previously paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15 through November 18, 2023, and also fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. These amounts were paid by someone else not connected to MAIA Biotechnology, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.
Now, diving right into MAIA Biotechnology, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.
Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear,
Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.
So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.